Equities

Genomma Lab Internacional SAB de CV

Genomma Lab Internacional SAB de CV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (MXN)16.91
  • Today's Change-0.37 / -2.14%
  • Shares traded2.45m
  • 1 Year change+11.32%
  • Beta0.6074
Data delayed at least 20 minutes, as of May 14 2024 21:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 09-May-24
Select bar for recommendation details.
Recommendations09-May-24
Buy1
Outperform4
Hold4
Underperform0
Sell0

Share price forecast in MXN

The 7 analysts offering 12 month price targets for Genomma Lab Internacional SAB de CV have a median target of 16.70, with a high estimate of 22.00 and a low estimate of 10.16. The median estimate represents a -1.53% decrease from the last price of 16.96.
High29.7%22.00
Med-1.5%16.70
Low-40.1%10.16

Earnings history & estimates in MXN

On Apr 24, 2024, Genomma Lab Internacional SAB de CV reported 1st quarter 2024 earnings of 0.39 per share.
The next earnings announcement is expected on Jul 24, 2024.
Average growth rate+3.46%
Genomma Lab Internacional SAB de CV reported annual 2023 earnings of 1.08 per share on Feb 21, 2024.
Average growth rate+5.91%
More ▼

Revenue history & estimates in MXN

Genomma Lab Internacional, S.A.B. de C.V. had 1st quarter 2024 revenues of 4.20bn. This missed the 4.21bn consensus estimate of the 2 analysts following the company. This was 0.46% above the prior year's 1st quarter results.
Average growth rate+1.11%
Genomma Lab Internacional, S.A.B. de C.V. had revenues for the full year 2023 of 16.47bn. This was 2.33% below the prior year's results.
Average growth rate+6.73%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.